Evidence map›Paper›PMID 35042981›Full record

ArticleBone marrow transplantation2022

Ocular graft-versus-host disease and dry eye disease after paediatric haematopoietic stem cell transplantation - incidence and risk factors.

Helene Jeppesen, Katrine Kielsen, Volkert Siersma, Jens Lindegaard, Hanne Olsen Julian, Steffen Heegaard, Henrik Sengeløv, Klaus Müller

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Helene JeppesenDepartment of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. helenejeppesen@gmail.com.ORCID http://orcid.org/0000-0001-7972-3698
Katrine KielsenDepartment of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-7167-012X
Volkert SiersmaThe Research Unit of General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-1941-2681
Jens LindegaardCopenhagen Eye Infirmary, Copenhagen, Denmark.
Hanne Olsen JulianDepartment of Ophthalmology, Mølholm Private Hospital, Vejle, Denmark.
Steffen HeegaardDepartment of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-5906-7670
Henrik SengeløvDepartment of Haematology, The Bone Marrow Transplantation Unit, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-5991-2958
Klaus MüllerDepartment of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-5278-1983
University of Copenhagen · DKCopenhagen University Hospital · DKLillebaelt Hospital · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular graft-versus-host disease (oGVHD) contributes substantially to morbidity after allogeneic haematopoietic stem cell transplantation (HSCT) but is sparsely investigated in children. We assessed incidence and risk factors for oGVHD and dry eye disease (DED) in a nationwide, single-centre study of 484 consecutive children receiving HSCT during the period 1980-2016. Ophthalmological examinations were performed before and annually at least until five years after HSCT. Twenty-five patients had DED before transplantation (5.6%). The cumulative incidence was 1.9% for acute oGVHD, 6.0% for chronic oGVHD, 8.7% for new onset DED, and 12.7% for new onset Corneal Fluorescein Staining (CFS). In adjusted Fine-Gray regression models, the use of Busulfan was a risk factor for developing acute oGVHD (HR 5.01, p = 0.03), and malignant disease was a risk factor for developing CFS (HR 2.00, p = 0.047). Younger recipient age was associated with reduced risk of DED when comparing children aged 0-4 years with 10-16 years (HR 0.33, p = 0.03). These data underscore the need of attention to DED and oGVHD in relation to HSCT leading to our recommendation of performing ophthalmic examinations in all children before HSCT, and after HSCT when needed, in order to secure diagnosis and treatment of these complications.

Indexed as

Dry Eye SyndromesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationChildHumansIncidenceRisk Factors

Identifiers

PMID35042981
OpenAlexW4205620569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.